Nutra Pharma, a biotech company developing treatments for Multiple Sclerosis (NYSE:MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (NYSE:AMN), and pain, reports that marketing and distribution company New Vitality has launched a test radio campaign to gauge the market acceptance of NPHC's pain reliever, Nyloxin™.
"This radio test represents the first broad exposure to our Nyloxin brand," Rik J Deitsch, CEO of NPHC, stated in the press release. "New Vitality is a powerhouse in direct sales and we are privileged to be working with them as they create awareness for our products. Radio advertising has already begun as test ads have been running in major markets across the U.S. over the past week. We believe that the consumer response will be positive, which will translate into sales growth for the products and the company."
Nyloxin is an all-natural drug containing proteins from cobra venom to relieve pain and inflammation. Research shows that cobra venom in controlled, minute doses is superior to morphine, though non-addictive.
Nyloxin is available as an oral spray for the treatment of a wide range of pain and inflammation, including lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia, as well as a topical gel for treating repetitive stress, arthritis, and joint pain. The drug is also available in extra strength formulations.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net